Clinical trial
Study to Evaluate a Subcutaneous Four Months Sustained-release Formulation of…
NCT00415246 · Ipsen, Industry · Terminated
Key facts
| NCT number | NCT00415246 |
|---|---|
| Title | Study to Evaluate a Subcutaneous Four Months Sustained-release Formulation of Triptorelin in Patients With Prostate Cancer |
| Official title | A Phase III, Single Arm, Multicentre Study to Evaluate the Efficacy and Safety of a Subcutaneous Four Months Sustained-release Formulation of Triptorelin, a Gonadotrophin Releasing Hormone Analogue in Patients With Prostate Cancer |
| Lead sponsor | Ipsen, Industry |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Prostate Cancer |
| Intervention type | Drug |
| Interventions | Triptorelin (Decapeptyl®) - Treatment 8 months (pivotal study) followed by a treatment extension of 8 months (extension study) |
| Enrollment | 100 |
| Start date | Nov 1, 2006 |
| Completion | Oct 1, 2007 |
| First posted | Dec 22, 2006 |
| Last update posted | Nov 22, 2019 |
| Countries | Belgium, France, Latvia, Lithuania, Poland, Spain, Ukraine, United Kingdom |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: